Six of the 10 biotechs that were ex­pect­ed to price their IPOs this week have now of­fi­cial­ly made the jump on­to the Nas­daq, con­tin­u­ing a record pace dat­ing back to 2020.

Vor Bio­phar­ma, Sid­dhartha Mukher­jee’s cell ther­a­py start­up, of­fi­cial­ly priced its 9,828,017 shares of com­mon stock Fri­day at $18 per share, rais­ing $176.9 mil­lion. Vor’s IPO, trad­ing un­der the tick­er $VOR, will close Feb. 9, with Gold­man Sachs, Ever­core ISI, Bar­clays and Stifel op­er­at­ing as bookrun­ners.

Vor said in ear­li­er SEC fil­ings that it would use the IPO fil­ing to ad­vance the two com­po­nents of its plat­form: A CAR-T for AML and a ge­net­i­cal­ly en­gi­neered stem cell trans­plant that makes the CAR-T safer, by re­mov­ing from healthy cells the pro­tein it tar­gets. Al­so of note, Vor ex­ceed­ed both its ini­tial com­pa­ny shares and the es­ti­mat­ed price point it list­ed in ear­li­er fil­ings.

Join­ing Vor this week was Lan­dos Bio­phar­ma, the Chris Garabe­di­an-backed oral au­toim­mune com­pa­ny, and Evax­ion Biotech, a Den­mark-head­quar­tered com­pa­ny us­ing AI im­munother­a­pies to tar­get can­cer and in­fec­tious dis­eases.

Lan­dos raised the sec­ond most of the three new Nas­daq ad­di­tions, pric­ing its 6,250,000 com­mon shares at $16 per share for an ini­tial haul of $100 mil­lion. Lan­dos’ IPO, un­der the tick­er $LABP, will close on Feb. 8 with JP Mor­gan, Jef­feries and SVB Leerink as the bookrun­ners. Lan­dos will of­fer un­der­writ­ers a 30-day op­tion of buy­ing an­oth­er 937,500 com­mon shares at the $16 price point.

Lan­dos’ of­fer­ing will be one to keep an eye on, as ini­tial fil­ings in­di­cat­ed a key fo­cus mov­ing for­ward will be its lead mol­e­cule BT-11, which is now fo­cused on ul­cer­a­tive col­i­tis and Crohn’s dis­ease but missed on all its pri­ma­ry end­points in IBD dur­ing a Phase II proof-of-con­cept study.

And Evax­ion will of­fer 3,000,000 shares at a price of $10 per share af­ter rais­ing $30 mil­lion, the com­pa­ny said. Trad­ing un­der the tick­er $EVAX, the IPO will close on Feb 9 with un­der­writ­ers hav­ing a 30-day op­tion of snap­ping up an­oth­er 450,000 ADSs at the IPO price point. Op­pen­heimer & Co. is op­er­at­ing as the sole bookrun­ner on the deal.

Ear­ly fil­ings show that Evax­ion plans on us­ing the IPO to fund four dif­fer­ent pro­grams in its port­fo­lio —most no­tably its lead can­di­date EVX-01, a per­son­al im­munother­a­py that us­es an AI plat­form to iden­ti­fy the best pro­tein tar­gets in each pa­tient. It’s in Phase I/IIa for three dif­fer­ent can­cers, where it’s be­ing test­ed in com­bo with PD-1 block­ers.

For on­go­ing track­ing of biotech IPOs in 2021, check out End­points News’ data­base here.

The FDA on Tuesday released a warning letter sent earlier this month to the Mason, OH-based site of Procter & Gamble Manufactura, raising questions about the list of ingredients on the label and in the electronic filing.

The warning says that for P&G’s over-the-counter Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion, there’s a “mismatched” list of active ingredients between the labeling and the electronic listing file. The listing file for the active ingredients did not match the active ingredients in the electronic file.

The Federal Trade Commission has gotten involved in a patent feud over Supernus’ Parkinson’s drug Apokyn, a case the agency said may have ‘‘significant implications” for patients who rely on the drug.

Sage Chemical won the first generic approval for its Apokyn formulation (also known as apomorphine hydrochloride injection) back in 2022. The non-ergoline dopamine agonist is approved to treat Parkinson’s symptoms during “off episodes,” such as difficulty moving, tremors and intense cramping. However, regulators specified that the approval pertained to the generic drug cartridges only, not the injector pen required for administration.